AA

Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
170001700017000Tofacitinib INTRODUCTION Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
Tofacitinib
Dupilumab Therapeutic Cheat Sheet
124141241412414DupilumabAtopic dermatitis (AD) is a common skin condition characterized by pruritus and occurs as a result of factors related to impaired skin barrier and immune response, as well as environmental and infectious agents. Patients with poor control on topical therapy are looking for safe and effective systemic treatments. We continue our series, Therapeutic Cheat Sheet, with a closer look at dupilumab, whic …
Dupilumab